Loading...
NASDAQ: AARD
Aardvark Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
Market Cap
$105.71M
52w High
$17.94
52w Low
$4.74
P/E
-2.16
Volume
65.28K
Outstanding Shares
21.77M
Skip DCF
The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.
Annual FCFF History
3
Derived observations
Positive FCFF Years
0
Total positive history
Positive Streak
0
Consecutive years
Latest FCFF
-$19.67M
Historical, not forecast
Decision Tree
Is FCFF positive and has it been for 3+ consecutive years?
no
Latest FCFF is not positive.
Is there enough operating history to anchor a DCF?
no
Only 1 years of public or statement history are available, so multiples are more decision-useful than a DCF here.
Company profile
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
CEOTien-Li Lee
SectorHealthcare
IndustryBiotechnology
Employees22
IPO dateFeb 13, 2025
Valuation
Forward P/E—
EV/EBITDA-5.47
Enterprise value$123.87M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE37.68%▲81.92%vs FY2023
Analyst consensus
RatingBuy
Target price$28.00▲476.73%
4
Buy
4
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 30, 2026
View
EPS
Actual vs estimate by quarter
Q2'25
ActualEst.
-$0.71
-$0.67
Q3'25
ActualEst.
-$0.66
-$0.60
Q4'25
ActualEst.
-$0.75
-$0.80
Q1'26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2'25
ActualEst.
—
—
Q3'25
ActualEst.
—
—
Q4'25
ActualEst.
—
—
Q1'26
Next Est.
—